A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Category: Uncategorized

  • Fourth NOAC FDA Approved for DVT, PE and Atrial Fibrillation: Savaysa (Edoxaban)

    Stephan Moll, MD writes…. Today (Jan 8th, 2015) the FDA approved yet another new oral anticoagulant, Savaysa (edoxaban), for the treatment of DVT and PE, as well as for atrial fibrillation. The FDA press release  is here (link).  Savaysa is the 4th of the NOACS now approved for VTE treatment. This table summarizes the differences, advantages and disadvantages comparing the 4 drugs. The…

  • Two Things Physicians Should Avoid

    Stephan Moll, MD writes (Dec 17, 2014)…  The American Society of Hematology (ASH) published last week as part of its Choosing Wisely® campaign two things that physicians dealing with DVT, PE and anticoagulants should avoid [ref 1].

  • Fascinating New “Anticoagulant”: It Protects from VTE, but Does Not Increase Bleeding

    Stephan Moll, MD writes (on Dec 8th, 2014)… A publication this week in the New England Journal of Medicine reports on an investigational drug that protects patients from VTE without increasing the risk of bleeding [reference below]. Too good to be true? Possibly, but may be not. Additional studies will have to tell.

  • VTE Prophylaxis in Hospitalized Patients: Guidance Document

    Stephan Moll, MD writes (on 12/5/2014)… Venous thromboembolism (VTE) prophylaxis in hospitalized patients is important; it is also mandated by the Joint Commission [ref].  We have developed at the University of North Carolina (UNC) a guidance document (link here; UNC VTE prophylaxis guidance document) as a resource for our health care professionals to assist in…

  • Antidotes for the New Oral Anticoagulants: Update

    Stephan Moll, MD writes (on Nov 7th, 2014)… A N Engl J Med publication this week [ref 1] reports on a new reversal agent (PER977 = Aripazine = ciraparantag) that may be effective against a number of different new oral anticoagulants.

  • Xarelto Dosing in Obese Patients

    Stephan Moll, MD writes…  Is there a dose change or limitation for the use of Xarelto® (rivaroxaban) in very obese or underweight patients?

  • Aspirin Decreases Recurrent DVT and PE

    Stephan Moll, MD writes… Aspirin is beneficial in preventing recurrent venous thromboembolism (VTE) in patients who have had a previous episode of unprovoked VTE and who have been treated with anticoagulant therapy, a publication in the journal Circulation re-confirms this week: Aspirin reduces the risk of recurrent VTE by more than a third without significantly increasing the risk…

  • Apixaban (Eliquis) FDA-Approval for DVT and PE Treatment

    Stephan Moll, MD writes…  Apixaban (Eliquis®) was approved by the FDA this week (Aug 21, 2014) for the treatment of DVT and PE.  The approval covers (a) acute DVT/PE management and (b) prevention of recurrent DVT/PE.